Prime Medicine, Inc.
PRME
Positions held
Your positionsPRME isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $649.33M | Enterprise value | $654.30M | Trailing P/E | — | Forward P/E | -4.03 |
| PEG | — | Price / book | 15.91 | Beta | 2.38 | Dividend yield | 0.00% |
| Revenue growth | 3.5% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -37.5% |
| Profit margin | 0.0% | ROE | -3.7% | ROA | -46.5% | Debt / equity | 2.83 |
| Current ratio | 3.06 | Free cash flow | -$75.78M | Analyst recommendation | strong_buy | Mean target | $7.11 |
| 52w high | $6.65 | 52w low | $2.67 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $0.9M | $0.8M | $1.2M | $1.1M | — |
| Op margin | -3750.9% | -5917.5% | -5800.5% | -4406.0% | -4787.2% | — |
| Net income | -$42.1M | -$49.1M | -$46.1M | -$50.6M | -$52.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.3M | -$50.7M | -$48.6M | -$54.0M | -$53.4M | — |
- Revenue +35% vs prior quarter ($1.2M vs $0.9M).
- Operating margin expanded to -3750.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0.0M | $0.0M | — |
| Op margin | -4498.1% | -6787.4% | — | — | — |
| Net income | -$201M | -$196M | -$198M | -$122M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$208M | -$202M | -$191M | -$117M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
2026-09-29 · Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-25 · Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says
2026-09-24 · Prime Medicine stock surges on FDA IND clearance
2026-09-24 · Prime Medicine Says US FDA Clears PM647 IND for Alpha-1 Antitrypsin Deficiency; Shares Rise After Hours
2026-09-24 · Anthropic AI Discovery Gene-Editing Stocks Falling
2026-09-23 · CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-17 · Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
2026-09-03 · Prime Medicine to Participate in Upcoming Investor Conferences
Price (daily)
Full chart · RSI · MACD · patterns